Evidence map›Paper›PMID 37812303›Full record

ArticleBreast cancer (Tokyo, Japan)2024

Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.

Yoshitaka Fujiki, Masahiro Kashiwaba, Mutsumi Sato, Junko Kawano, Megumi Teraoka, Shuichi Kanemitsu, Yoshiaki Rai, Tetsuhiko Taira, Yoshiaki Sagara, Yasuyo Ohi and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Yoshitaka FujikiDepartment of Breast and Endocrine Surgical Oncology, Hakuaikai Social Medical Corporation, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-0098, Japan.
Masahiro KashiwabaDepartment of Breast and Endocrine Surgical Oncology, Hakuaikai Social Medical Corporation, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-0098, Japan.
Mutsumi SatoDepartment of Breast and Endocrine Surgical Oncology, Hakuaikai Social Medical Corporation, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-0098, Japan.
Junko KawanoDepartment of Breast and Endocrine Surgical Oncology, Hakuaikai Social Medical Corporation, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-0098, Japan.
Megumi TeraokaDepartment of Breast and Endocrine Surgical Oncology, Hakuaikai Social Medical Corporation, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-0098, Japan.
Shuichi KanemitsuDepartment of Breast and Endocrine Surgical Oncology, Hakuaikai Social Medical Corporation, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-0098, Japan.
Yoshiaki RaiDepartment of Breast and Endocrine Surgical Oncology, Hakuaikai Social Medical Corporation, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-0098, Japan.
Tetsuhiko TairaDepartment of Medical Oncology, Hakuaikai Social Medical Corporation, Sagara Hospital, Kagoshima, Japan.
Yoshiaki SagaraDepartment of Radiology, Hakuaikai Social Medical Corporation, Sagara Hospital, Kagoshima, Japan.
Yasuyo OhiDepartment of Pathology, Hakuaikai Social Medical Corporation, Sagara Hospital, Kagoshima, Japan.
Uiree JoDepartment of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Young-Won LeeDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Sae Byul LeeDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Gyungyub GongDepartment of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Young Kee ShinLaboratory of Molecular Pathology and Cancer Genomics, Research Institute of Pharmaceutical Sciences and College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Mi Jeong KwonVessel-Organ Interaction Research Center, College of Pharmacy, Kyungpook National University, 80 Daehak-Ro, Buk-Gu, Daegu, 41566, Republic of Korea. mjkwon94@knu.ac.kr.ORCID http://orcid.org/0000-0002-7599-878X
Yasuaki SagaraDepartment of Breast and Endocrine Surgical Oncology, Hakuaikai Social Medical Corporation, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-0098, Japan. yas794@mail.harvard.edu.
National Sagamihara Hospital · JPUlsan College · KRPanasonic (Japan) · JPKyungpook National University · KRSeoul National University · KR

Funding

National Research Foundation of Korea NRF-2020R1A5A2017323National Research Foundation of Korea NRF-2022R1A2C1007293National Research Foundation of Korea NRF-2022R1A6A1A03046247
6 · The paper itself

Abstract

backgroundAccurate prediction of the risk of recurrence is crucial for optimal treatment decisions in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. The GenesWell BCT is a molecular assay to predict the 10-year risk of distant metastasis. In this study, we evaluated the long-term prognostic value of the GenesWell BCT assay.

methodsThe BCT score was assessed in patients with HR-positive/HER2-negative early breast cancer who did not receive chemotherapy. We compared the 15-year distant metastasis-free survival (DMFS) between risk groups classified based on the BCT score. The risk of early (0-5 years) and late (5-15 years) recurrence was evaluated based on the BCT score classification.

resultsAccording to the BCT score, 366 patients from Japan and Korea were categorized as BCT low risk (83.6%) and high risk (16.4%) for distant metastasis. Median follow-up time was 17.4 years. The 15-year DMFS rate was significantly lower in the BCT high-risk group (63.3%) than in the BCT low-risk group (93.6%) (P < 0.001). The BCT risk group was an independent prognostic factor for 15-year DMFS (hazard ratio, 4.59; 95% confidence interval 2.13-9.88; P < 0.001). Furthermore, the BCT score was a significant predictor of late recurrence (5-15 years) in patients aged ≤ 50 years and those aged > 50 years, and added prognostic information to traditional clinical prognostic factors.

conclusionThe BCT score can identify patients at low risk for recurrence who may not require adjuvant chemotherapy or extended endocrine therapy, regardless of age.

Indexed as

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoplasm Recurrence, LocalPrognosisRisk FactorsErb-b2 Receptor Tyrosine KinasesAsian womenGenesWell BCT scoreHormone receptor-positive/HER2-negative breast cancerLate recurrencePrognostic value

Identifiers

PMID37812303
PMCPMC10764379
OpenAlexW4387440997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.